Neuron23 announces groundbreaking Phase 2 trial in Early Parkinson’s Disease?and under an exclusive agreement, Quest Diagnostics will deploy the assay in the advanced diagnostics laboratory in San Juan Capistrano, CA to identify trial candidates. This rigorous screening process is designed to maximize the likelihood of enrolling people who have the highest potential for benefit from treatment with NEU-411 – those with LRRK2-driven Parkinson’s disease – significantly enhancing the trial's potential impact and likelihood of success. Read more here: https://lnkd.in/eShmssCC?
We're excited to share details about our Phase 2 NEULARK trial of NEU-411, a brain-penetrant, potent and selective inhibitor of #LRRK2, in people living with early #Parkinsons disease (PD). The NEULARK trial represents a significant #precisionmedicine advancement in how we can effectively identify and measure therapeutic impact in LRRK2-driven PD, estimated to affect up to 30% of people living with the disease. Listen in as Chief Medical Officer Sam Jackson, EVP of Drug Discovery Steve Wood, and Executive Director of Clinical and Digital Development Fatta B. Nahab MD, FAAN, FANA, discuss the importance of NEU-411 and how this innovative trial in PD differentiates itself. Our LRRK2 program is a key driver of innovation within our neuroimmunology pipeline, and we are on track to initiate this trial early in 2025. Read more here: https://lnkd.in/eShmssCC